Rapid Detection of COVID-19 by Portable and Connected Biosensor
NCT ID: NCT04367142
Last Updated: 2024-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2020-08-24
2023-05-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
positive SARS-Cov2
100 patients with a positive diagnosis of SARS-CoV-2
COVID-19 RT-PCR
Nasopharyngeal swabs for COVID-19 RT-PCR
Biosensor
Portable and Connected Biosensor viral
negative SARS-Cov2
100 patients with a negative diagnosis of SARS-CoV-2 defined by the gold standard by the medical team
COVID-19 RT-PCR
Nasopharyngeal swabs for COVID-19 RT-PCR
Biosensor
Portable and Connected Biosensor viral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID-19 RT-PCR
Nasopharyngeal swabs for COVID-19 RT-PCR
Biosensor
Portable and Connected Biosensor viral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to a Reference Health Establishment in an emergency unit, hospitalisation or intensive care unit for suspicion of SARS-CoV-2 infection, regardless of the clinical presentation and degree of severity.
* Patient to be diagnosed using a PCR test on nasopharyngeal swab.
* Social insured
Exclusion Criteria
* Patient refusal to participate
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Enagnon Kazali ALIDJINOU, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU lille
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A01147-32
Identifier Type: OTHER
Identifier Source: secondary_id
2020_36
Identifier Type: -
Identifier Source: org_study_id